Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review

Pyoderma gangrenosum (PG) is a rare ulcerative skin disease that presents a therapeutic challenge. Tumour necrosis factor alpha (TNFα) inhibitors have been reported to successfully control PG. Our aim was to systematically evaluate and compare the clinical effectiveness of TNFα inhibitors in adults with PG. A literature search including databases such as PubMed, Embase, Scopus, and Web of Science was conducted, using search terms related to PG and TNFα inhibitors. Studies and case reports were included if patients were diagnosed with PG, over the age of 18 and administered TNFα inhibitor. A total of 3212 unique citations were identified resulting in 222 articles describing 356 patients being included in our study. The study we report found an 87% (95% CI: 83%‐90%) response rate and a 67% (95% CI: 62%‐72%) complete response rate to TNFα inhibitors. No statistically significant differences in the response rates (P = 0.6159) or complete response rates (P = 0.0773) to infliximab, adalimumab, and etanercept were found. In our study TNFα inhibitors demonstrated significant effectiveness with response and complete response rates supporting the use of TNFα inhibitors to treat PG in adults. Our study suggests that there is no significant difference in effectiveness among infliximab, adalimumab, and etanercept.

[1]  T. Ota,et al.  Intestinal Behçet’s disease with pyoderma gangrenosum successfully treated with the combination therapy of adalimumab and glucocorticoids , 2018, Modern rheumatology.

[2]  K. Kridin,et al.  Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis , 2018, American Journal of Clinical Dermatology.

[3]  Rosie Qin,et al.  Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts , 2018, JAMA dermatology.

[4]  B. Feagan,et al.  Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease , 2018, Digestive Diseases and Sciences.

[5]  Andrew M. Armenta,et al.  Delayed diagnosis of post-surgical pyoderma gangrenosum: A multicenter case series and review of literature , 2018, International journal of surgery case reports.

[6]  C. Ahn,et al.  Pyoderma gangrenosum: a review of pathogenesis and treatment , 2018, Expert review of clinical immunology.

[7]  I. Ceccherini,et al.  LPIN2 gene mutation in a patient with overlapping neutrophilic disease (pyoderma gangrenosum and aseptic abscess syndrome) , 2018, JAAD case reports.

[8]  L. Misery,et al.  PASH syndrome (pyoderma gangrenosum, acne and hidradenitis suppurativa): a disease with genetic heterogeneity , 2018, The British journal of dermatology.

[9]  P. Lin,et al.  SAPHO syndrome associated with hidradenitis suppurativa and pyoderma gangrenosum successfully treated with adalimumab and methotrexate: a case report and review of the literature , 2018, International journal of dermatology.

[10]  G. Foulke,et al.  Suppression of pathergy in pyoderma gangrenosum with infliximab allowing for successful tendon debridement , 2017, JAAD case reports.

[11]  P. Modiano,et al.  Successful combined antibiotic therapy with oral clindamycin and oral rifampicin for pyoderma gangrenosum in patient with PASH syndrome , 2017, JAAD case reports.

[12]  S. Granter,et al.  Wounds That Would Not Heal: Pyoderma Gangrenosum. , 2017, The American journal of medicine.

[13]  T. Schoeller,et al.  Reconstructive microsurgical approach for the treatment of pyoderma gangrenosum. , 2018, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[14]  B. Tod,et al.  Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab. , 2017, Dermatology online journal.

[15]  G. Carreño-Tarragona,et al.  Dramatic resolution of disseminated pyoderma gangrenosum associated with monoclonal gammopathy after therapy with bortezomib and dexamethasone , 2017, International wound journal.

[16]  E. Çalışkan Er: YAG Laser Ablation: An Adjuvant Treatment for Medically Resistant Pyoderma Gangrenosum. , 2017, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[17]  B. Abraham,et al.  Resolution of Pyoderma Gangrenosum With Vedolizumab in a Crohnʼs Patient: 2017 Presidential Poster Award: 1973 , 2017 .

[18]  Teresa Ro,et al.  Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa. , 2017, The Journal of clinical and aesthetic dermatology.

[19]  N. Sami,et al.  Pyoderma gangrenosum in pregnancy successfully treated with infliximab and prednisone , 2017, JAAD case reports.

[20]  J. Mascaró,et al.  Multifocal and refractory pyoderma gangrenosum: Possible role of cocaine abuse , 2017, The Australasian journal of dermatology.

[21]  E. Berti,et al.  Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis) , 2017, The British journal of dermatology.

[22]  T. Ruzicka,et al.  Familial Mediterranean fever patients with hidradenitis suppurativa , 2017, International journal of dermatology.

[23]  P. Shetty,et al.  Pyoderma gangrenosum in Sjögren's syndrome and its successful treatment with topical application of etanercept , 2017, International journal of rheumatic diseases.

[24]  P. R. Mydlarski,et al.  Plasmablastic-like lymphoma arising within chronic pyoderma gangrenosum , 2017, JAAD case reports.

[25]  R. Seabury,et al.  Severe neutrophilic dermatosis following submental deoxycholic acid administration , 2017, Clinical toxicology.

[26]  M. F. Chin,et al.  Successful Treatment of Autoimmune Disease-Associated Pyoderma Gangrenosum With the IL-1 Receptor Antagonist Anakinra: A Case Series of 3 Patients. , 2017, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[27]  M. Beylot-Barry,et al.  Pyoderma gangrenosum with extensive pulmonary involvement , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[28]  R. Galimberti,et al.  Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients , 2017, International journal of dermatology.

[29]  Jeung-Hoon Lee,et al.  Treatment of Recalcitrant Pyoderma Gangrenosum with Ulcerative Colitis by Adalimumab Injection , 2017, Annals of dermatology.

[30]  L. Davis,et al.  A case of autoinflammatory skin and bone disease flared by a change in osteoporosis management , 2017, JAAD case reports.

[31]  T. Dainichi,et al.  High level of serum human interleukin‐18 in a patient with pyogenic arthritis, pyoderma gangrenosum and acne syndrome , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[32]  P. Yeo,et al.  Neutrophilic Dermatoses as a Continuous Spectrum: An Illustrative Case. , 2016, Annals of the Academy of Medicine, Singapore.

[33]  W. Payne,et al.  Severe Bilateral Lower Extremity Pyoderma Gangrenosum , 2016, Eplasty.

[34]  A. Gottlieb,et al.  High‐dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum , 2016, Dermatologic therapy.

[35]  A. Puri,et al.  Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis , 2016, Intestinal research.

[36]  R. Galimberti,et al.  The role of interleukin-1β in pyoderma gangrenosum , 2016, JAAD case reports.

[37]  I. Burón-Alvarez,et al.  Refractory pyoderma gangrenosum treated with platelet‐rich plasma , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[38]  Masoomeh Khajehnoori,et al.  A case of surgically treated peristomal pyoderma gangrenosum in a patient with rheumatoid arthritis , 2016, Journal of surgical case reports.

[39]  S. L. Ortega,et al.  [Peristomal pyoderma gangrenosum after rectal adenocarcinoma in the context of colonic and complex perianal Crohn's disease]. , 2016 .

[40]  D. Rigopoulos,et al.  Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine. , 2016, Acta dermatovenerologica Croatica : ADC.

[41]  D. Selva,et al.  Pyoderma gangrenosum of the eyelid. , 2016, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[42]  M. Schmuth,et al.  Surgical treatment of pyoderma gangrenosum with negative pressure wound therapy and split thickness skin grafting under adequate immunosuppression is a valuable treatment option: Case series of 15 patients. , 2016, Journal of the American Academy of Dermatology.

[43]  P. Baade,et al.  Diagnosis of an additional in situ melanoma does not influence survival for patients with a single invasive melanoma: A registry‐based follow‐up study , 2016, The Australasian journal of dermatology.

[44]  M. Allez,et al.  Certolizumab pegol – A new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn’s disease , 2016, The Journal of dermatological treatment.

[45]  N. De Maria,et al.  Complete resolution of non‐necrotizing lung granuloma and pyoderma gangrenosum after restorative proctocolectomy in a woman with severe ulcerative colitis and cytomegalovirus infection , 2016, Clinical case reports.

[46]  A. Lohse,et al.  [Multiple abscesses after a cruise along the Latin American coast]. , 2016, Der Internist.

[47]  Dhyan Rajan,et al.  IBD LIVE Case Series-Case 6. , 2016, Inflammatory bowel diseases.

[48]  Víctor Amo Trillo,et al.  [Peristomal pyoderma gangrenosum after rectal adenocarcinoma in the context of colonic and complex perianal Crohn's disease]. , 2016, Gastroenterologia y hepatologia.

[49]  F. J. Céspedes-Guirao,et al.  Management of pyoderma gangrenosum with combination of systemic treatment, vacuum-assisted closure and synthetic dermal substitute , 2016, European Journal of Plastic Surgery.

[50]  A. Lohse,et al.  Multiple Abszesse nach Südamerikakreuzfahrt , 2016, Der Internist.

[51]  W. Koltun,et al.  Refractory Peristomal Pyoderma Gangrenosum Successfully Treated With Intravenous Immunoglobulin: A Case Report , 2015, The American Journal of Gastroenterology.

[52]  S. Goerdt,et al.  Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[53]  B. Xia,et al.  Pyoderma gangrenosum of articulations carpi associated with ulcerative colitis: one case report. , 2015, International journal of clinical and experimental medicine.

[54]  M. Camilleri,et al.  Postoperative pyoderma gangrenosum (PG): the Mayo Clinic experience of 20 years from 1994 through 2014. , 2015, Journal of the American Academy of Dermatology.

[55]  C. Zouboulis,et al.  Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. Treatment with infliximab. , 2015, Journal of dermatological case reports.

[56]  E. Lindwall,et al.  Novel PSTPIP1 gene mutation in a patient with pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome. , 2015, Seminars in arthritis and rheumatism.

[57]  Toshiyuki Yamamoto,et al.  Peristomal pyoderma gangrenosum: A report of three cases , 2015, The Journal of dermatology.

[58]  H. Williams,et al.  Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial , 2015, BMJ : British Medical Journal.

[59]  E. Bendia,et al.  Finally, recurrent pyoderma gangrenosum treated with Adalimumab: case report and review of the literature , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[60]  M. Gonçalo,et al.  Pyoderma gangrenosum: challenges and solutions , 2015, Clinical, cosmetic and investigational dermatology.

[61]  E. Maverakis,et al.  Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. , 2015, Acta dermato-venereologica.

[62]  D. Meyersburg Multilokuläres superfizielles Pyoderma gangraenosum oder PAPA-Syndrom – erfolgreiche Therapie mit Ustekinumab , 2015, Aktuelle Dermatologie.

[63]  O. Hilberg,et al.  Pulmonary manifestations of pyoderma gangrenosum: 2 cases and a review of the literature. , 2015, Respiratory medicine.

[64]  G. Carretero-Hernández,et al.  Infliximab como opción terapéutica en pioderma gangrenoso mamario bilateral postquirúrgico refractario , 2015 .

[65]  R. McDonald,et al.  Recalcitrant pyoderma gangrenosum treated with parenteral iron sucrose therapy , 2015, JAAD case reports.

[66]  N. Parrish,et al.  Treatment of Refractory Crohn's Disease and Pyoderma Gangrenosum with a Combination Regimen of Rifaximin, Gentamicin and Metronidazole , 2015, Case Reports in Gastroenterology.

[67]  Han Pei-pe Pyoderma gangrenosum associated with inflammatory bowel disease , 2015 .

[68]  J. L. P. L. Peña,et al.  Enfermedad de Behçet y pioderma gangrenoso refractario a terapia convencional con respuesta a infliximab , 2015 .

[69]  S. Chimenti,et al.  PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition. , 2015, Journal of the American Academy of Dermatology.

[70]  M. Sánchez-Conde,et al.  Behçet disease and refractory pyoderma gangrenosum with response to infliximab. , 2015, Revista clinica espanola.

[71]  K. Chayama,et al.  Successful Use of Adalimumab for Treating Pyoderma Gangrenosum with Ulcerative Colitis under Corticosteroid-tapering Conditions. , 2015, Internal medicine.

[72]  A. Gaspari,et al.  Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated With infliximab. , 2015, Cutis.

[73]  G. Zerboni,et al.  Cutaneous manifestations and gastrointestinal disorders: Report of two emblematic cases. , 2015, La Clinica terapeutica.

[74]  L. Rönnblom,et al.  Recurrent pyoderma gangrenosum and cystic acne associated with leucocyte adhesion deficiency due to novel mutations in ITGB2: successful treatment with infliximab and adalimumab. , 2015, Acta dermato-venereologica.

[75]  G. Morrison,et al.  Successful use of adalimumab to treat pyoderma gangrenosum, acne and suppurative hidradenitis (PASH syndrome) following colectomy in ulcerative colitis , 2015, International Journal of Colorectal Disease.

[76]  Mio Nakamura,et al.  Pyoderma Gangrenosum Following the Revision of a Breast Reconstruction and Abdominoplasty , 2014 .

[77]  D. Fanoni,et al.  Association of Pyoderma Gangrenosum, Acne, and Suppurative Hidradenitis (PASH) Shares Genetic and Cytokine Profiles With Other Autoinflammatory Diseases , 2014, Medicine.

[78]  M. Ye,et al.  Pyoderma Gangrenosum: A Review of Clinical Features and Outcomes of 23 Cases Requiring Inpatient Management , 2014, Dermatology research and practice.

[79]  D. Fanoni,et al.  Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome , 2014, Clinical and experimental immunology.

[80]  E. Cinotti,et al.  Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis , 2014, Clinical and experimental dermatology.

[81]  N. Teich Failure of sublesional infliximab injection for refractory parastomal pyoderma gangrenosum in a patient with Crohn’s disease , 2014, Techniques in Coloproctology.

[82]  C. GuillermoBannura,et al.  PIODERMA GANGRENOSO GIGANTE DE CURSO FULMINANTE ASOCIADO A ENFERMEDAD INFLAMATORIA INTESTINAL , 2014 .

[83]  Recep Ak,et al.  A case of granulomatosis with polyangiitis and pyoderma gangrenosum successfully treated with infliximab and rituximab. , 2014, International journal of rheumatic diseases.

[84]  N. Yun,et al.  Peritonsillar Involvement in Pyoderma Gangrenosum associated with Ulcerative Colitis , 2014, Intestinal research.

[85]  M. Morgan,et al.  A report of two patients with a history of pyoderma gangrenosum where total knee arthroplasty was performed under prophylactic immunosuppression , 2014 .

[86]  C. Lyon,et al.  Severe Back Pain in a Young Patient with Pyoderma Gangrenosum and Crohn’s Disease Controlled with Anti-tumor Necrosis Factor Therapy: Sterile Osteomyelitis , 2014, Dermatology and Therapy.

[87]  Hyun Jong Lee,et al.  Zosteriform transient acantholytic dermatosis , 2014, The Journal of dermatology.

[88]  N. Teich,et al.  Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis. , 2014, Journal of Crohn's & colitis.

[89]  O. Ishikawa,et al.  Clinical analysis of leg ulcers and gangrene in rheumatoid arthritis , 2013, The Journal of dermatology.

[90]  P. Gjersvik,et al.  [A horseshoe-shaped wound on the back]. , 2013, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[91]  A. Swaminath,et al.  Gastrointestinal: Severe inflammatory bowel disease‐associated pyoderma gangrenosum , 2013, Journal of gastroenterology and hepatology.

[92]  Jack Green,et al.  Mycophenolate use in dermatology: A clinical audit , 2013, The Australasian journal of dermatology.

[93]  J. Mekkes,et al.  Six patients with pyoderma gangrenosum successfully treated with infliximab , 2013, International journal of dermatology.

[94]  D. Alpert,et al.  Refractory postsurgical pyoderma gangrenosum in a patient with Beckwith Wiedemann syndrome: response to multimodal therapy , 2013, BMJ Case Reports.

[95]  Saleh Elwir,et al.  A Case Report of a Patient with Crohnʼs Disease Complicated by Pyoderma Gangrenosum Treated with Intravenous Immunoglobulin: 1419 , 2013 .

[96]  Mardem Machado de Souza,et al.  Biological therapy for pyoderma gangrenosum , 2013 .

[97]  J. Klode,et al.  Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients , 2013, Orphanet Journal of Rare Diseases.

[98]  Daniela Simian,et al.  [Treatment of inflammatory bowel disease with infliximab: experience in 25 patients]. , 2013, Revista medica de Chile.

[99]  S. Sinha,et al.  Pyoderma gangrenosum: guideline for wound practitioners. , 2013, Journal of wound care.

[100]  T. Lobaton,et al.  Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease , 2013, Digestive Diseases and Sciences.

[101]  L. Guidi,et al.  A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery. , 2013, Journal of Crohn's & colitis.

[102]  S. Katz,et al.  Massive pyoderma gangrenosum in a 77 year old female with Crohn's disease responsive to adalimumab. , 2013, Journal of Crohn's & colitis.

[103]  M. Figueira,et al.  N015 Patient education on their disease as a determinant on the progression of complications. The role of specialized nursing , 2013 .

[104]  Tomoyuki Ito,et al.  A case of aseptic abscesses syndrome treated with corticosteroids and TNF-alpha blockade , 2013, Modern rheumatology.

[105]  R. Quera,et al.  [Treatment of inflammatory bowel disease with infliximab: experience in 25 patients]. , 2013, Revista medica de Chile.

[106]  E. El-Omar,et al.  Topical tacrolimus 0.1% ointment for treatment of cutaneous Crohn’s Disease , 2013, BMC Research Notes.

[107]  B. Rao,et al.  Superficial pyoderma gangrenosum treated with infliximab: a case report. , 2012, Cutis.

[108]  V. Bruzzese Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor α therapy. , 2012, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[109]  A. Gottlieb,et al.  Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. , 2012, Journal of the American Academy of Dermatology.

[110]  R. Guedes,et al.  Treatment of thalidomide resistant pyoderma gangrenosum with etenercept. , 2012, Acta dermatovenerologica Croatica : ADC.

[111]  S. Glover,et al.  IVIG Treatment for Refractory Pyoderma Gangrenosum in Patients with Inflammatory Bowel Disease: 1265 , 2012 .

[112]  N. Nguyen,et al.  A large shin ulcer after minor trauma: please do not debride! , 2012, Gastroenterology.

[113]  M. Cottone,et al.  Multifocal pyoderma gangrenosum resistant to infliximab in active ulcerative colitis: don't forget the role of cyclosporin. , 2012, Inflammatory bowel diseases.

[114]  M. Cordero-Coma,et al.  Refractory Pyoderma Gangrenosum of the Orbit and the Lacrimal Sac , 2012, Orbit.

[115]  S. D. Del Giacco,et al.  Idiopathic pyoderma gangrenosum: successful resolution with infliximab therapy and pro-inflammatory cytokines assessment. , 2012, Acta dermato-venereologica.

[116]  A. Pandya,et al.  The use of etanercept in the treatment of peristomal pyoderma gangrenosum , 2012, Clinical and experimental dermatology.

[117]  E. Makino,et al.  Successful treatment with infliximab for refractory pyoderma gangrenosum associated with inflammatory bowel disease , 2012, The Journal of dermatology.

[118]  T. Vogt,et al.  Adalimumab: a Treatment Option for Pyoderma Gangrenosum After Failure of Systemic Standard Therapies , 2012, Dermatology and Therapy.

[119]  Brian L. Huang,et al.  Facial ulceration in a patient with Crohn's disease. , 2012, Gastroenterology.

[120]  J. J. S. Maestrojuan,et al.  Pioderma gangrenoso asociado a enfermedad inflamatoria intestinal. Descripción de 2 casos con buena respuesta a infliximab , 2012 .

[121]  R. Owen,et al.  Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum , 2012, Clinical and experimental dermatology.

[122]  C. Cubero,et al.  Pyoderma Gangrenosum Associated With Inflammatory Bowel Disease. Report of Two Cases With Good Response to Infliximab , 2012 .

[123]  M. Tanioka,et al.  Refractory pyoderma gangrenosum associated with ulcerative colitis successfully treated with infliximab. , 2012, Dermatology online journal.

[124]  M. Hoang,et al.  Case records of the Massachusetts General Hospital. Case 1-2012. An 82-year-old man with persistent ulcers on the hands. , 2012, The New England journal of medicine.

[125]  R. Bosch,et al.  [Pyoderma gangrenosum: a report of 15 cases and review of the literature]. , 2012, Actas dermo-sifiliograficas.

[126]  E. Doménech,et al.  Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease. , 2011, Inflammatory bowel diseases.

[127]  I. Klein,et al.  "Fulminant" Behçet disease. , 2011, Presse medicale.

[128]  A. Langewouters,et al.  Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab , 2011, The Journal of dermatological treatment.

[129]  J. Grant-Kels,et al.  Cutaneous simulants of infectious disease , 2011, International journal of dermatology.

[130]  N. Teich Infliximab anaphylaxis in siblings. , 2011, Inflammatory bowel diseases.

[131]  J. Aitken,et al.  Body‐site distribution of skin cancer, pre‐malignant and common benign pigmented lesions excised in general practice , 2011, The British journal of dermatology.

[132]  Zhenwu Lin,et al.  Failure of anakinra treatment of pyoderma gangrenosum in an IBD patient and relevance to the PSTPIP1 gene. , 2011, Inflammatory bowel diseases.

[133]  I. Katayama,et al.  Clinical implications of leukocytapheresis using a centrifugal cell separator for steroid‐resistant pyoderma gangrenosum associated with inflammatory bowel disease , 2011, The Journal of dermatology.

[134]  P. Itin,et al.  A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents. , 2011, Advances in skin & wound care.

[135]  E. Mazokopakis,et al.  Improvement of ulcerative pyoderma gangrenosum with hyperbaric oxygen therapy , 2011, Dermatologic therapy.

[136]  E. Ben-Chetrit,et al.  Laryngeal involvement in Behcet’s disease—a challenge for treatment , 2013, Clinical Rheumatology.

[137]  T. Maurer,et al.  Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. , 2010, Archives of dermatology.

[138]  F. Baglieri,et al.  THERAPEUTIC HOTLINE: Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report , 2010, Dermatologic therapy.

[139]  R. Chalmers,et al.  Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab. , 2010, Dermatology online journal.

[140]  Hiroaki Nakamura,et al.  Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis , 2010, Modern rheumatology.

[141]  T. Shaver,et al.  Clinical efficacy of etanercept for treatment of PAPA syndrome. , 2010, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[142]  I. Pedro,et al.  Utilidad del infliximab en pioderma gangrenoso no asociado a enfermedad inflamatoria intestinal , 2010 .

[143]  Parviz Goshtasby,et al.  A novel approach to the management of pyoderma gangrenosum complicating reduction mammaplasty. , 2010, Aesthetic surgery journal.

[144]  E. Efremidou,et al.  Crohn's Disease Associated Pyoderma Gangrenosum Treated with Adalimumab , 2010 .

[145]  Y. Bar-dayan,et al.  Coexistent pyoderma gangrenosum and tibialis anterior myositis as presenting manifestations of Crohn’s disease: case report and review of the literature , 2011, Rheumatology International.

[146]  M. English,et al.  A CASE OF PYODERMA GANGRENOSUM OF THE LUNG , 2009 .

[147]  F. Castiglione,et al.  Monster parastomal pyoderma gangrenosum effectively treated by topical tacrolimus. , 2009, Journal of Crohn's & colitis.

[148]  R. Sarkany,et al.  Superficial granulomatous pyoderma treated preoperatively with infliximab , 2009, Clinical and experimental dermatology.

[149]  J. Callen,et al.  Mycophenolate mofetil as therapy for pyoderma gangrenosum. , 2009, Archives of dermatology.

[150]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[151]  N. Alkhouri,et al.  Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. , 2009, Inflammatory bowel diseases.

[152]  Z. Barta,et al.  Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone. , 2009, World journal of gastroenterology.

[153]  Byung Soo Kim,et al.  A Case of Recalcitrant Pyoderma Gangrenosum Treated by Infliximab. , 2009 .

[154]  M. Schaller,et al.  Septic shock after treatment of pyoderma gangrenosum with infliximab. , 2009, Acta dermato-venereologica.

[155]  F. Ermiş,et al.  Pyoderma gangrenosum treated with infliximab in inactive ulcerative colitis. , 2008, Inflammatory bowel diseases.

[156]  Antonio Rodríguez,et al.  Response to Infliximab in Atypical Pyoderma Gangrenosum Associated With Ulcerative Colitis , 2008, The American Journal of Gastroenterology.

[157]  L. Barnes,et al.  Pyoderma gangrenosum manifesting as a cavitating lung lesion , 2008, Clinical and experimental dermatology.

[158]  R. Kirsner,et al.  Pyoderma Gangrenosum in a Patient with Bruton's X-linked Agammaglobulinemia: Shared Pathogenesis of Altered Tumor Necrosis Factor Alpha? , 2008, The Journal of clinical and aesthetic dermatology.

[159]  N. Kang,et al.  Treatment of pyoderma gangrenosum with the anti-TNFalpha drug - Etanercept. , 2008, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[160]  T. Gambichler,et al.  Intravenous immunoglobulin for pyoderma gangrenosum , 2008, The British journal of dermatology.

[161]  A. Marzano,et al.  Widespread idiopathic pyoderma gangrenosum evolved from ulcerative to vegetative type: a 10‐year history with a recent response to infliximab , 2008, Clinical and experimental dermatology.

[162]  F. Kerdel,et al.  Pyoderma gangrenosum – rebel without a cure? , 2008, International journal of dermatology.

[163]  W. Koltun,et al.  Management of peristomal pyoderma gangrenosum. , 2008, Journal of the American College of Surgeons.

[164]  E. Adışen,et al.  Treatment of Idiopathic Pyoderma Gangrenosum with Infliximab: Induction Dosing Regimen or On-Demand Therapy? , 2008, Dermatology.

[165]  J. Sánchez-Carazo,et al.  [Two cases of eruptive pyoderma gangrenosum associated with cocaine use]. , 2008, Actas dermo-sifiliograficas.

[166]  A. Qureshi,et al.  Adalimumab for treatment of pyoderma gangrenosum , 2007, The British journal of dermatology.

[167]  D. Sánchez-Muñoz,et al.  Improving Transparency in Medical Journals , 2007, The American Journal of Gastroenterology.

[168]  S. Moschella Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases , 2007, International journal of dermatology.

[169]  T. Gress,et al.  Simultaneous Onset of Ulcerative Colitis and Disseminated Pyoderma Gangrenosum , 2007, Case Reports in Gastroenterology.

[170]  R. Caprilli,et al.  Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases. , 2007, Inflammatory bowel diseases.

[171]  R. Kirsner,et al.  Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series , 2007, International journal of dermatology.

[172]  F. Luyten,et al.  Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis , 2007, Clinical Rheumatology.

[173]  S. Christen-Zäch,et al.  Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis , 2007, Dermatology.

[174]  S. Bombardieri,et al.  Improvement of Idiopathic Pyoderma Gangrenosum During Treatment With Anti-Tumor Necrosis Factor Alfa Monoclonal Antibody , 2007, The international journal of lower extremity wounds.

[175]  C. Tait,et al.  Use of infliximab in pyoderma gangrenosum , 2007, The Australasian journal of dermatology.

[176]  J. Gisbert,et al.  Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: response to infliximab. , 2007, Inflammatory bowel diseases.

[177]  D. I. Smith,et al.  Adalimumab treatment for pyoderma gangrenosum. , 2007, Archives of dermatology.

[178]  R. Golouh,et al.  Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease. , 2006, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.

[179]  B. Ehst,et al.  Adalimumab Therapy for Recalcitrant Pyoderma Gangrenosum , 2006, Journal of burns and wounds.

[180]  M. Novelli,et al.  An exuberant inflammatory response to E coli: implications for the pathogenesis of ulcerative colitis and pyoderma gangrenosum , 2006, Gut.

[181]  M. Rice,et al.  Wet colostomy and peristomal skin breakdown. , 2006, Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society.

[182]  M. Kaatz,et al.  Fatal outcome of pyoderma gangrenosum with multiple organ involvement and partially responding to Infliximab , 2006 .

[183]  D. Cohen,et al.  The treatment of pyoderma gangrenosum using etanercept. , 2006, Journal of the American Academy of Dermatology.

[184]  S. Abramson,et al.  Treatment of Pyoderma Gangrenosum (PG) with Infliximab in Leukocyte Adhesion Deficiency (LAD) Type 1 , 2006 .

[185]  M. Blanes,et al.  Pyoderma gangrenosum treated with anti‐TNF alpha therapy (etanercept) , 2006, Clinical and experimental dermatology.

[186]  J. Sánchez-Carazo,et al.  Systemic absorption of topical tacrolimus in Pyoderma gangrenosum. , 2006, Acta dermato-venereologica.

[187]  G. I. Leontiadis,et al.  Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report. , 2005, Romanian journal of gastroenterology.

[188]  A. Forbes,et al.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial , 2005, Gut.

[189]  M. Kaur,et al.  Severe recalcitrant pyoderma gangrenosum treated with infliximab , 2005, The British journal of dermatology.

[190]  R. Kelly,et al.  Pyoderma gangrenosum complicated by herpes simplex virus infection , 2005, The Australasian journal of dermatology.

[191]  R. Kirsner,et al.  Refractory pyoderma gangrenosum peristomal ulcer and sinus tract treated with micronized cadaveric dermis. , 2005, Journal of the American Academy of Dermatology.

[192]  A. Krag,et al.  [Treatment with infliximab of peristomal pyoderma gangrenosum in ulcerative colitis]. , 2005, Ugeskrift for laeger.

[193]  V. Hubbard,et al.  Systemic pyoderma gangrenosum responding to infliximab and adalimumab , 2005, The British journal of dermatology.

[194]  I. Uthman,et al.  Successful treatment of recalcitrant pyoderma gangrenosum with infliximab complicated by tuberculosis despite negative screening tests , 2005, Clinical and experimental dermatology.

[195]  A. Hoffbrand,et al.  Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab , 2005, Clinical and experimental dermatology.

[196]  F. Castiglione,et al.  Infliximab in the treatment of extra‐intestinal manifestations of Crohn's disease , 2005, Scandinavian journal of rheumatology.

[197]  G. Goldenberg,et al.  Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis , 2005, The Journal of dermatological treatment.

[198]  M. Yaron,et al.  The effect of infliximab on extraintestinal manifestations of Crohn’s disease , 2005, Rheumatology International.

[199]  I. Lawrance INFLIXIMAB IN THE MANAGEMENT OF THE EXTRA‐INTESTINAL MANIFESTATIONS OF CROHN's DISEASE , 2004, Journal of gastroenterology and hepatology.

[200]  Sidney R. Cohen,et al.  Treatment of Pyoderma Gangrenosum with Infliximab in Crohn's Disease , 2004, Digestive Diseases and Sciences.

[201]  F. Bermejo,et al.  Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab. , 2004, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[202]  Madhuri Reddy,et al.  Rheumatoid arthritis‐associated inflammatory leg ulcers: a new treatment for recalcitrant wounds , 2004, International wound journal.

[203]  J. Lear,et al.  Infliximab as a treatment for recalcitrant pyoderma gangrenosum , 2004, Clinical and experimental dermatology.

[204]  G. Schuler,et al.  Successful treatment of therapy‐resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody) , 2004, The British journal of dermatology.

[205]  G. Cuppari,et al.  Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. , 2004, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[206]  I. Grosman,et al.  Control of hemorrhage from a gastric Dieulafoy's lesion using argon plasma coagulation , 2003, American Journal of Gastroenterology.

[207]  M. Regueiro,et al.  Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease , 2003, American Journal of Gastroenterology.

[208]  D. Mimouni,et al.  Infliximab for peristomal pyoderma gangrenosum , 2003, The British journal of dermatology.

[209]  R. Kirsner,et al.  Infliximab: A Treatment Option for Ulcerative Pyoderma Gangrenosum , 2003 .

[210]  F. Grange,et al.  Corticosteroid-Resistant Pyoderma gangrenosum Associated with Crohn’s Disease: Rapid Cure with Infliximab , 2002, Dermatology.

[211]  M. Romero-Gómez,et al.  Infliximab induces remission of pyoderma gangrenosum. , 2002, European journal of gastroenterology & hepatology.

[212]  M. Vatn,et al.  Pyoderma Gangrenosum Associated with Crohn Disease: Effect of TNF- α Blockade with Infliximab , 2002, Scandinavian journal of gastroenterology.

[213]  J. Triantafillidis,et al.  Favorable Response to Infliximab Treatment in a Patient with Active Crohn Disease and Pyoderma Gangrenosum , 2002, Scandinavian journal of gastroenterology.

[214]  M. Vatn,et al.  Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab. , 2002, Scandinavian journal of gastroenterology.

[215]  D. Sheldon,et al.  Peristomal pyoderma gangrenosum. , 2001, Journal of the American College of Surgeons.

[216]  O. Ennis,et al.  Para-ileostomy pyoderma gangrenosum , 2001, The Lancet.

[217]  M. Lebwohl,et al.  Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. , 2001, Archives of dermatology.

[218]  S. Hanauer,et al.  Treatment of pyoderma gangrenosum (PG) complicating Crohn's disease (CD) with infliximab , 2001 .

[219]  J. Callen,et al.  Clinical features and treatment of peristomal pyoderma gangrenosum. , 2000, JAMA.

[220]  R. Kozarek,et al.  Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. , 2000, Archives of surgery.

[221]  M. Lebwohl,et al.  Cutaneous manifestations of inflammatory bowel disease , 2000, Journal of the European Academy of Dermatology and Venereology : JEADV.

[222]  D. S. Santa Cruz,et al.  Neutrophilic dermatoses. , 1989, Seminars in dermatology.

[223]  F. Suchy,et al.  Pustular pyoderma gangrenosum associated with ulcerative colitis in childhood. Report of two cases and review of the literature. , 1986, Journal of the American Academy of Dermatology.